Early-stage research update on an Alzheimer's combination therapy, outlining biomarker assessments, safety overview, and considerations for designing future trials.
Key Takeaways
- Randomized double-blind placebo-controlled RoAD study enrolled eight participants
- Plasma analyses showed directional changes in Alzheimer hallmark proteins over three timepoints
- Company described biomarker results as exploratory due to limited samples and will power future trials